DK1131070T3 - Farmaceutisk sammensætning til modificeret frigivelse af en insulin- sensibilisator og metformin - Google Patents

Farmaceutisk sammensætning til modificeret frigivelse af en insulin- sensibilisator og metformin

Info

Publication number
DK1131070T3
DK1131070T3 DK99964483T DK99964483T DK1131070T3 DK 1131070 T3 DK1131070 T3 DK 1131070T3 DK 99964483 T DK99964483 T DK 99964483T DK 99964483 T DK99964483 T DK 99964483T DK 1131070 T3 DK1131070 T3 DK 1131070T3
Authority
DK
Denmark
Prior art keywords
metformin
pharmaceutical composition
modified release
insulin sensitizer
sensitizer
Prior art date
Application number
DK99964483T
Other languages
Danish (da)
English (en)
Inventor
Karen Lewis
Nicola Jayne Lilliott
Donald Colin Mackenzie
Vincenzo Re
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1131070(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9824866.9A external-priority patent/GB9824866D0/en
Priority claimed from GBGB9824869.3A external-priority patent/GB9824869D0/en
Priority claimed from GBGB9824867.7A external-priority patent/GB9824867D0/en
Priority claimed from GBGB9912191.5A external-priority patent/GB9912191D0/en
Priority claimed from GBGB9912193.1A external-priority patent/GB9912193D0/en
Priority claimed from GBGB9912190.7A external-priority patent/GB9912190D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DK1131070T3 publication Critical patent/DK1131070T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK99964483T 1998-11-12 1999-11-08 Farmaceutisk sammensætning til modificeret frigivelse af en insulin- sensibilisator og metformin DK1131070T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9824866.9A GB9824866D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9824869.3A GB9824869D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9824867.7A GB9824867D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912191.5A GB9912191D0 (en) 1999-05-25 1999-05-25 Novel composition and use
GBGB9912193.1A GB9912193D0 (en) 1999-05-25 1999-05-25 Novel composition and use
GBGB9912190.7A GB9912190D0 (en) 1999-05-25 1999-05-25 Novel composition and use
PCT/EP1999/008704 WO2000028989A1 (fr) 1998-11-12 1999-11-08 Composition pharmaceutique a liberation modifiee d'un agent de sensibilisation a l'insuline, et d'un autre agent antidiabetique

Publications (1)

Publication Number Publication Date
DK1131070T3 true DK1131070T3 (da) 2008-11-17

Family

ID=27547326

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99964483T DK1131070T3 (da) 1998-11-12 1999-11-08 Farmaceutisk sammensætning til modificeret frigivelse af en insulin- sensibilisator og metformin

Country Status (36)

Country Link
EP (3) EP1992337A1 (fr)
JP (1) JP2002529504A (fr)
KR (1) KR100643833B1 (fr)
CN (1) CN1230162C (fr)
AR (1) AR024228A1 (fr)
AT (1) ATE406889T1 (fr)
AU (1) AU768994B2 (fr)
BG (2) BG109852A (fr)
BR (1) BR9915285A (fr)
CA (1) CA2351058A1 (fr)
CY (1) CY1108587T1 (fr)
CZ (1) CZ20011629A3 (fr)
DE (1) DE69939485D1 (fr)
DK (1) DK1131070T3 (fr)
DZ (1) DZ2936A1 (fr)
EA (2) EA011633B1 (fr)
ES (1) ES2312221T3 (fr)
HK (1) HK1040910B (fr)
HR (1) HRP20010343B1 (fr)
HU (1) HUP0104303A3 (fr)
ID (1) ID28783A (fr)
IL (2) IL143002A0 (fr)
MY (1) MY124695A (fr)
NO (1) NO20012303L (fr)
NZ (1) NZ511614A (fr)
OA (1) OA11677A (fr)
PE (1) PE20001238A1 (fr)
PL (1) PL347634A1 (fr)
PT (1) PT1131070E (fr)
SI (1) SI1131070T1 (fr)
SK (1) SK287038B6 (fr)
TR (1) TR200101333T2 (fr)
TW (2) TWI251487B (fr)
UY (1) UY25799A1 (fr)
WO (1) WO2000028989A1 (fr)
YU (1) YU37301A (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
AU2007201729B2 (en) * 1999-12-23 2010-02-25 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
KR20020063260A (ko) 1999-12-23 2002-08-01 노파르티스 아게 당 대사 장애를 치료하기 위한 혈당강하제의 용도
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
US8257744B2 (en) * 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
BR0115390A (pt) * 2000-11-03 2004-02-25 Andrx Corp Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
CA2725833A1 (fr) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments
NZ527930A (en) * 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
FR2822069B1 (fr) * 2001-03-19 2003-06-20 Lipha Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete
CN100356907C (zh) * 2001-06-08 2007-12-26 恩德制药公司 利用丙烯酸酯聚合物的控释剂型和其制备方法
JP2004536842A (ja) * 2001-07-10 2004-12-09 エアロファーム テクノロジー インコーポレイテッド トログリタゾンおよびビグアナイドを含むコア製剤
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
US6824790B2 (en) 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
WO2003105809A1 (fr) * 2002-06-17 2003-12-24 Themis Laboratories Private Limited Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1589951B1 (fr) * 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Utilisation d'un melange de deux ou de plusieurs materiaux enteriques afin de reguler la liberation de medicaments via une membrane ou une matrice dans des therapies systemiques
US7976853B2 (en) 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
AR045330A1 (es) * 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
GEP20084570B (en) 2003-10-31 2008-12-25 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
JP4739189B2 (ja) 2004-04-14 2011-08-03 武田薬品工業株式会社 固形製剤
CA2563325C (fr) * 2004-04-29 2010-06-22 Lotus Pharmaceutical Co., Ltd. Pastilles a liberation orale modifiee et leur procede de preparation
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
KR100657785B1 (ko) * 2005-02-19 2007-04-16 한국유나이티드제약 주식회사 글리메피리드, 메트포르민 및 은행엽엑스를 함유하는 약학적 조성물
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
MXPA05010977A (es) * 2005-10-12 2007-04-11 Abdala Leopoldo Espinosa Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
MXPA05014092A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
AU2006328328B2 (en) * 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
WO2008073282A2 (fr) * 2006-12-07 2008-06-19 Schering Corporation Formulation de matrice sensible au ph
WO2008109462A2 (fr) * 2007-03-02 2008-09-12 Farnam Companies, Inc. Compositions à libération prolongée utilisant des matières cireuses
TW200906383A (en) * 2007-08-02 2009-02-16 Handok Pharmaceuticals Co Ltd Sustained-release formulation comprising metformin acid salt
CN101801371B (zh) 2007-09-10 2012-11-28 詹森药业有限公司 可用作sglt抑制剂的化合物的制备方法
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
CN101548961B (zh) * 2008-04-03 2011-05-04 单宝华 一种治疗糖尿病及肥胖症的口服胶囊制剂
WO2010026467A2 (fr) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Forme pharmaceutique à libération prolongée de principe actif hautement soluble
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
SG10201500258WA (en) 2009-10-14 2015-03-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
LT2568988T (lt) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
CN102970981A (zh) * 2010-07-06 2013-03-13 詹森药业有限公司 糖尿病协同治疗制剂
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
CN102631332A (zh) * 2012-04-28 2012-08-15 邹立兴 一种伏格列波糖片剂及其制备方法
KR101409330B1 (ko) * 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
EP2958548A1 (fr) * 2013-02-19 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Procédé de production de formulations de gliclazide
UA122403C2 (uk) * 2014-12-17 2020-11-10 Емпрос Фарма Аб Композиція орлістату та акарбози з модифікованим вивільненням для лікування ожиріння і пов'язаних метаболічних порушень
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
US4538469A (en) * 1983-07-29 1985-09-03 Panametrics, Inc. Integrated threshold arming method and apparatus
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1989008650A1 (fr) 1988-03-08 1989-09-21 Pfizer Inc. Agents hypoglycemiques de thiazolidinedione
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
WO1991007107A1 (fr) 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
JP2630016B2 (ja) * 1990-05-21 1997-07-16 ヤマハ株式会社 吹奏感付加器を有する電子管楽器
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
HUT65619A (en) 1990-07-03 1994-07-28 Yamanouchi Pharma Co Ltd Process for producing bisheterocyclic compounds and pharmaceutical preparations containing them
US5334604A (en) 1990-08-23 1994-08-02 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1992018501A1 (fr) 1991-04-11 1992-10-29 The Upjohn Company Derives de thiazolidinedione, production et utilisation desdits derives
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (fr) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
AU3959193A (en) 1992-04-10 1993-11-18 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type II-diabetes
WO1993022445A1 (fr) 1992-05-05 1993-11-11 The Upjohn Company Procede de production de metabolites de pioglitazone
NZ253742A (en) 1992-07-03 1997-06-24 Smithkline Beecham Plc Heterocyclylaminoalkoxy substituted phenyl derivatives and pharmaceutical compositions
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
RU2071783C1 (ru) * 1993-09-07 1997-01-20 Ессентукский центральный военный санаторий Способ получения средства для лечения сахарного диабета
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
RU2114617C1 (ru) * 1996-09-27 1998-07-10 Юрий Георгиевич Каминский Антидиабетическое средство на основе янтарной кислоты
IL132032A0 (en) * 1997-03-24 2001-03-19 Galderma Res & Dev Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment

Also Published As

Publication number Publication date
CA2351058A1 (fr) 2000-05-25
TW592694B (en) 2004-06-21
ATE406889T1 (de) 2008-09-15
AU768994B2 (en) 2004-01-15
TR200101333T2 (tr) 2001-10-22
HUP0104303A3 (en) 2003-12-29
KR20010080419A (ko) 2001-08-22
HUP0104303A2 (hu) 2002-03-28
NZ511614A (en) 2003-12-19
PL347634A1 (en) 2002-04-22
EA200601145A1 (ru) 2009-04-28
PT1131070E (pt) 2008-11-19
PE20001238A1 (es) 2001-01-11
EA200100541A1 (ru) 2001-10-22
WO2000028989A1 (fr) 2000-05-25
JP2002529504A (ja) 2002-09-10
EA011633B1 (ru) 2009-04-28
EP1992337A1 (fr) 2008-11-19
NO20012303D0 (no) 2001-05-10
EP1131070A1 (fr) 2001-09-12
BR9915285A (pt) 2001-08-07
EA007610B1 (ru) 2006-12-29
TW200418453A (en) 2004-10-01
BG109852A (bg) 2008-11-28
CN1230162C (zh) 2005-12-07
HK1040910A1 (en) 2002-06-28
KR100643833B1 (ko) 2006-11-10
CY1108587T1 (el) 2014-04-09
OA11677A (en) 2005-01-12
AU3033800A (en) 2000-06-05
EP1813273A1 (fr) 2007-08-01
BG65351B1 (bg) 2008-03-31
ES2312221T3 (es) 2009-02-16
SI1131070T1 (sl) 2008-12-31
IL143002A0 (en) 2002-04-21
UY25799A1 (es) 2000-12-29
HK1040910B (en) 2009-06-26
AR024228A1 (es) 2002-09-25
CN1348369A (zh) 2002-05-08
EP1131070B1 (fr) 2008-09-03
CZ20011629A3 (cs) 2001-12-12
DE69939485D1 (de) 2008-10-16
YU37301A (sh) 2005-06-10
TWI251487B (en) 2006-03-21
IL143002A (en) 2007-02-11
SK6442001A3 (en) 2001-12-03
HRP20010343A2 (en) 2002-06-30
BG105568A (en) 2002-01-31
MY124695A (en) 2006-06-30
HRP20010343B1 (hr) 2010-11-30
SK287038B6 (sk) 2009-10-07
DZ2936A1 (fr) 2004-03-15
ID28783A (id) 2001-07-05
NO20012303L (no) 2001-07-04

Similar Documents

Publication Publication Date Title
NO20012303L (no) Farmasoytisk sammensetning for modifisert frigjoring av et insulinsensibiliserende middel og et annet antidiabetisk middel
DK1066049T3 (da) Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
PT998272E (pt) Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol
DK1273294T3 (da) Farmaceutisk præparat af fenofibrat med höj biologisk tilgængelighed og fremgangsmåde til dets fremstilling
DK0991654T3 (da) Hidtil ukendte derivater af 2-(iminomethyl)aminophenyl, deres fremstilling, deres anvendelse til medikamenter og farmaceutiske præparater indeholdende samme
DK0622408T3 (da) Sammensætning og fremgangsmåde til fremstilling af gelatinfrie, bløde kapsler
DK0998473T3 (da) Krystalmodifikation af et N-phenyl-2-pyrimidinaminderivat, fremgangsmåder til fremstilling deraf samt dets anvendelse
IS5190A (is) Lyfjafræðileg blanda N-Píperídínó-3-pýrazólkarboxamíð afleiðum, söltum og lausnarsamböndum til munnlegrar inntöku
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
DK1086113T3 (da) Benzothiepin-1,1-dioxidderivater, fremgangsmåde til deres fremstilling, lægemidler med indhold af disse forbindelser og deres anvendelse
DK1108424T3 (da) Matrixtablet til langvarig frisætning af
DK0996444T3 (da) Behandling af diabetes med thiazolidindion og metformin
NO20011157D0 (no) Benzenderivater og farmasøytisk anvendelse derav
DK199900234U4 (da) Paroxetin-methansulfonat i krystallinsk form, farmaceutisk præparat indeholdende dette og andvendelse af forbindelsen til f
NO20001914D0 (no) <alfa>-Aryl-N-alkylnitroner og farmasøytiske blandinger som inneholder slike
NO20003070D0 (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
NO20010487D0 (no) Disubstituert maleimidforbindelse og farmasöytisk anvendelse herav
NO20012351D0 (no) Farmasöytisk sammensetning for modifisert frigjöring av insulinsensibiliserende middel
DK2017269T3 (da) Krystallinsk form II af ritonavirindeholdende farmaceutisk sammensætning og fremstilling heraf
DK1003383T3 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
DK0719775T3 (da) Substituerede derivater af 4-phenylthiazol, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger, der inde
DK1003528T3 (da) Fremgangsmåde til forøgelse af biotilgængeligheden af fexofenadin og dets derivater
IS5223A (is) Lyfjasamsetningar af tizoxaníði og nitazoxaníði
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater